Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
AST SpaceMobile adopted a Senior Management Change of Control Severance Policy for its CEO, President, and senior executives. The policy provides lump-sum cash payments (2.0x salary/bonus for CEO, 1.5x for others) and accelerated vesting of equity awards if executives are terminated without cause or resign for constructive discharge following a change of control. This arrangement is designed to ensure management stability and focus during potential acquisition scenarios.
Kodiak Gas Services M&A Deal with Distributed Power Solutions, LLC
Kodiak Gas Services, Inc. filed an amendment to provide pro forma financial information regarding its previously completed acquisition of Distributed Power Solutions, LLC (DPS). The filing includes unaudited pro forma condensed combined statements of operations for the six months ended June 30, 2026, treating the acquisition as if it had occurred on January 1, 2025.
Kodiak Gas Services, Inc. filed a Certificate of Elimination to its Amended and Restated Certificate of Incorporation to eliminate all matters related to its Series A Preferred Stock. The company stated that no shares of the Series A Preferred Stock are currently outstanding and no further shares will be issued under the previous Certificate of Designation.
Nexalin Technology received a notification from the Nasdaq Hearings Panel granting a conditional extension to regain compliance with listing standards. The company must demonstrate a minimum bid price of $1.00 for 20 consecutive trading sessions by September 28, 2026, and meet the $2.5 million stockholders' equity requirement by January 4, 2027.
Exascale Labs Holdings reported fiscal year 2026 revenue of $14.8 million, a 111% increase year-over-year driven by its GPU-as-a-Service platform. The company also highlighted its recent Nasdaq listing following a business combination and the appointment of a new CFO.
Term
FY2026
“Fiscal year 2026 was the year we laid the foundation to become a public company. To establish our readiness for this next phase, we grew our GPU-as-a-Service business, deepened our infrastructure partnership with Compal, and closed the agreement that brought Exascale to Nasdaq.”
Hoansoo Lee, Chief Executive Officer
“Exascale’s revenue grew 111% this past fiscal year, powered by a 124% increase in our intelligent computing power service and a customer renewal rate around 68%, and the balance sheet is now stronger following the close of the business combination.”
CervoMed announced pharmacokinetic and regulatory updates for its lead drug candidate, neflamapimod, including a new 50 mg oral tablet formulation and the FDA's removal of a previous drug exposure limit. These developments allow the company to advance a 100 mg twice-daily dosing regimen in future clinical trials, which is expected to achieve higher drug concentrations and improve patient convenience compared to prior three-times-daily dosing.
U S Physical Therapy $171M Debt Financing with Bank of America, National Association
U.S. Physical Therapy, Inc. entered into a 45-month forward-starting interest rate swap agreement with Bank of America with an initial notional amount of $170.6 million. The swap fixes the variable interest rate on the company's existing term debt at 4.578% per annum effective June 30, 2027, through April 14, 2031. This transaction is designed to hedge interest rate risk associated with the company's Fourth Amended and Restated Credit Agreement.
Accendra Health announced that Kenneth Gardner-Smith will assume the role of President and CEO on October 5, 2026, succeeding Edward A. Pesicka. Mr. Pesicka will retire from the Board and enter into a 30-month consulting agreement to ensure a smooth transition, during which his existing equity awards will continue to vest.
Faraday Future Intelligent Electric Divestiture to AIxCrypto Holdings, Inc for $200M
Faraday Future Intelligent Electric Inc. entered into a non-binding term sheet to sell its robotics business to its majority-owned subsidiary, AIxCrypto Holdings, Inc., for $200 million. The consideration will be paid in AIxC common and non-voting convertible preferred stock, and the transaction is being reviewed by a Special Committee of the Board due to its related-party nature.
NeOnc Technologies has scheduled an in-person End-of-Phase 1 Type B meeting with the FDA for November 17, 2026, to discuss the clinical development of NEO212. The company intends to seek feedback on Phase 2 study design, patient populations, and potential accelerated approval pathways following encouraging Phase 1 results in glioblastoma and brain metastases.
San Juan Basin Royalty Trust provided an operational update regarding administrative expenses and the conclusion of a 2017–2020 joint interest audit. The Trustee reported a $976,000 year-over-year decrease in G&A expenses following the transition to Argent Trust Company and determined that pursuing further recovery from the Hilcorp audit was not cost-effective.
Inhibrx Biosciences, Inc. has updated its corporate investor presentation, which is being used for meetings and conferences with the investment community. The presentation provides a summary of the company's business strategy and clinical pipeline updates for its investigational product candidates.
AAR CORP. reported Q1 fiscal 2027 sales of $918 million, a 24% increase year-over-year, driven by strong demand in the aviation aftermarket. The company achieved adjusted EBITDA of $117 million and announced a definitive agreement to acquire a 65% controlling interest in MRO Holdings to scale its heavy maintenance capabilities.
Term
Q1 2027
Earnings call
Sep 29, 2026, 8:00 AM ET
“This was a very strong start to our fiscal year. Our airline customers continue to experience strong demand for air travel, which in turn is driving strong demand for our services, as evidenced by our results this quarter.”
John M. Holmes, AAR’s Chairman, President and CEO
“Our strategy has been successful over the last several years as we have delivered above-market growth and consistent margin expansion. The acquisition of MRO Holdings will further propel this growth and drive a meaningful step-up in our margin profile.”
PCB Bancorp's Board of Directors has authorized a new share repurchase program to buy back up to 700,000 shares of its common stock. The program is authorized for one year through September 22, 2027, and the company intends to utilize a Rule 10b5-1 trading plan to facilitate the repurchases.
RingCentral, Inc. has scheduled its 2026 Annual Meeting of Stockholders for November 2, 2026. Because the meeting date is more than 30 days earlier than the anniversary of the previous year's meeting, the company has established October 9, 2026, as the new deadline for shareholder proposals and director nominations.
Viking Acquisition Corp I M&A Deal with NorthStar Earth & Space Inc.
Viking Acquisition Corp. I (VACI) announced that its previously disclosed business combination with NorthStar Earth & Space Inc. is expected to close on September 30, 2026. Following the merger, the combined company will be renamed NorthStar Earth & Space Enterprises, Inc. and will transfer its listing to the NYSE American under the ticker 'NSTR' on October 1, 2026.
StandardAero announced that Kimberly Ernzen will step down as Chief Operating Officer effective September 28, 2026. She will remain with the company through December 31, 2026, to support leadership transition efforts under a transition agreement currently being finalized.
Azitra, Inc. entered into a sales agreement with A.G.P./Alliance Global Partners to establish an at-the-market (ATM) offering program. The company may sell up to $3.5 million of common stock from time to time at its discretion, though no shares have been sold as of the filing date. Proceeds are intended for working capital and general corporate purposes.
CAMP4 Therapeutics held an Analyst Day meeting to present details on its planned Phase 1/2 ASCEND clinical trial of CMP-002 for SYNGAP1-related disorder. The company provided a comprehensive data presentation and updated its corporate pipeline overview, detailing the trial's design, inclusion criteria, and therapeutic dosing expectations.
Greenland Mines Ltd. entered into a securities purchase agreement with institutional investors to issue 1,320,000 shares of common stock in a direct registered offering. The company expects to receive approximately $17.2 million in net proceeds to fund its Greenland mining operations and general working capital. Additionally, the company terminated its previously established $50 million at-the-market offering program with A.G.P./Alliance Global Partners.
Herb Cross resigned as CFO, Principal Financial Officer, and Principal Accounting Officer of Jasper Therapeutics effective October 9, 2026. The company appointed CEO Jeet Mahal as interim Principal Financial Officer and Rick Ruiz as interim Principal Accounting Officer to fill the vacancies.
SilverBox Corp IV announced that its units, Class A ordinary shares, and warrants have been delisted from the New York Stock Exchange effective September 28, 2026. The securities have transitioned to the OTCID Basic Market and are now trading under the new ticker symbols SBXUF, SBXDF, and SBXWF, respectively.
McCormick & Company provided a status update on its pending acquisition of Unilever's foods business, noting that the deal's anticipated closing will cause its current auditor, Ernst & Young LLP, to lose independence. Consequently, the company has appointed KPMG LLP as its new independent registered public accounting firm effective for the fiscal year ending November 30, 2027.
Keurig Dr Pepper completed the divestiture of its indirect equity interests in Chobani and the sale of certain assets, including leasehold interests in two Pennsylvania facilities, to Chobani. The total consideration of $925 million consists of $525 million in cash and an $800 million promissory note maturing in December 2026. This transaction represents a full exit from the company's investment in Chobani alongside an asset disposal.
IDT Corporation reported record financial results for its fourth quarter and full fiscal year 2026, with annual revenue increasing 5% to $1.298 billion. Full-year net income attributable to IDT rose 14% to $86.6 million, driven by strong performance in its NRS and Fintech segments. The company achieved a significant expansion in consolidated gross margin, which reached 38.3% for the fiscal year.
A securities class action lawsuit has been filed against Unicycive Therapeutics and certain officers in the U.S. District Court for the Northern District of California. The lawsuit alleges violations of federal securities laws regarding public statements about the company's New Drug Application for oxylanthanum carbonate. Unicycive stated it believes the claims are meritless and intends to vigorously defend the action.
Gianluca Fuggetta resigned as Senior Vice President of Finance, principal financial officer, and principal accounting officer effective September 30, 2026. Gene Mack, the company's current President and CEO, has been appointed to serve as interim Chief Financial Officer effective October 1, 2026, while the company searches for a permanent replacement.
Wintergreen Acquisition Debt Financing Update with MACRO DREAM Holdings Limited
Wintergreen Acquisition Corp. issued an unsecured promissory note for $184,635 to its sponsor, MACRO DREAM Holdings Limited, to fund a trust account deposit. This deposit extends the company's deadline to complete its initial business combination from September 30, 2026, to October 30, 2026. The note is non-interest bearing and may be converted into units at $10.00 per unit upon the closing of a business combination.
Isabella Bank Signs $18.3M M&A Deal with Grand River Commerce, Inc.
Isabella Bank Corporation provided a status update on its pending acquisition of Grand River Commerce, Inc., announcing the mailing of election materials to shareholders. Grand River shareholders have until October 23, 2026, to elect to receive cash (estimated at $5.71 per share) or Isabella common stock (estimated exchange ratio of 0.1413) as merger consideration.
Precision Optics reported record fiscal year 2026 revenue of $31.5 million, a 65% increase year-over-year, driven by a doubling of production revenue to $28.1 million. While the company reported a net loss of $3.6 million for the year, it significantly improved its cash position to $9.8 million and issued FY 2027 revenue guidance of $30 million to $33 million.